Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SF3B3 | Q15393 | 10/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14396018 | 1.00 | SF3B3 (0.55) | SF3B3 | |
| SCHEMBL16705942 | 1.00 | SF3B3 (0.55) | SF3B3 | |
| SCHEMBL15297008 | 1.00 | SF3B3 (0.55) | SF3B3 | |
| SCHEMBL12298672 | 1.00 | SF3B3 (0.55) | SF3B3 | |
| SCHEMBL15297013 | 1.00 | SF3B3 (0.55) | SF3B3 | |
| SCHEMBL15297009 | 1.00 | SF3B3 (0.55) | SF3B3 | |
| SCHEMBL14397315 | 1.00 | SF3B3 (0.55) | SF3B3 | |
| SCHEMBL14396324 | 0.95 | SF3B3 (0.55) | SF3B3 | |
| SCHEMBL14397399 | 0.95 | SF3B3 (0.51) | SF3B3 | |
| SCHEMBL14396935 | 0.95 | SF3B3 (0.51) | SF3B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119113-A1 | COMPOSITIONS AND METHODS FOR SPLICEOSOME-TARGETED THERAPIES | INSTITUTE CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2024-06-06 | — | — | WO | claimed |
| US-20240148688-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | UNIV CALIFORNIA (US) | 2024-05-09 | — | — | US | claimed |
| EP-4361136-A1 | COMPOUND FOR THE TREATMENT OF GLIOBLASTOMA | Universidad De Córdoba (ES) | 2024-05-01 | — | — | EP | claimed |
| EP-4284519-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | The Regents of the University of California (US) | 2023-12-06 | — | — | EP | claimed |
| CN-116829142-A | Methods for treating and ameliorating cancer | 加利福尼亚大学董事会 | 2023-09-29 | — | — | CN | claimed |
| US-20230190707-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNOTHERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2023-06-22 | — | — | US | claimed |
| EP-4149483-A2 | COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNOTHERAPY | Fred Hutchinson Cancer Center (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2022165398-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | WO | claimed |
| US-12623988-B2 | Scaleable preparation of polyketides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2025151487-A2 | SMALL-MOLECULE INHIBITORS OF ADAR1 | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-07-17 | — | — | WO | disclosed |
| JP-2025065209-A | Methods for Treating and Ameliorating Cancer | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 2025-04-17 | — | — | JP | disclosed |
| US-12172988-B2 | Anticancer and antifungal splice modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-24 | — | — | US | disclosed |
| US-12172988-B2 | Anticancer and antifungal splice modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024254465-A2 | METHODS FOR PROMOTING EXPANSION OF HUMAN CD34+ CELLS IN VIVO AND FOR PROMOTING NEURAL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2007110705-A2 | MACROLIDE AS INHIBITORS OF MHC CLASS II | NOVIMMUNE SA (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-7256178-B2 | Physiologically active substances | EISAI CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7256178-B2 | Physiologically active substances | EISAI CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| US-20060079572-A1 | Novel bioactive substance | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| US-7026352-B1 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2006-04-11 | — | — | US | disclosed |
| EP-1380579-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079572-A1 | Novel bioactive substance | CASP7, MMP7, BMP4 | SF3B3 2363/4885 |
| US-12623988-B2 | Scaleable preparation of polyketides | SF3B5, RPS5, RPS25 | SF3B3 95/4885 |
| US-12172988-B2 | Anticancer and antifungal splice modulators | SF3B5, U2AF1, CWC15 | SF3B3 28/4885 |
| US-20240148688-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | ABL1, FLT3, MCL1 | SF3B3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.